Inventor · disambiguated record
Nels P. Nielson
Also filed as: NIELSON II NELS PETER · NIELSON NELS · NIELSON NELS P
16 granted patents·17 pending applications·79 citations·filing 2014–2024
92Inventor score
Files withPOTENZA THERAPEUTICS INC9ALECTOR LLC6FIVE PRIME THERAPEUTICS INC4SURFACE ONCOLOGY INC4BYOMASS INC3
Top patents by PatentIndex Score
33 records- 0196US10676525B2Anti-TREM2 antibodies and methods of use thereofALECTOR LLC·Filed 2018·Granted Jun 9, 2020·13 cites·60 claims
- 0294US9713641B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2017·Granted Jul 25, 2017·35 cites·20 claims
- 0393US10711062B2Anti-CD33 antibodies and methods of use thereofALECTOR LLC·Filed 2018·Granted Jul 14, 2020·7 cites·77 claims
- 0491US11306144B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Apr 19, 2022·6 cites·45 claims
- 0590US11814431B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 14, 2023·3 cites·48 claims
- 0690US11634489B2Anti-TREM2 antibodies and methods of use thereofALECTOR LLC·Filed 2020·Granted Apr 25, 2023·2 cites·32 claims
- 0790US11254743B2Anti-CD33 antibodies and methods of use thereofALECTOR LLC·Filed 2020·Granted Feb 22, 2022·2 cites·20 claims
- 0888US10793637B2Antibodies that bind CD39 and uses thereofSURFACE ONCOLOGY INC·Filed 2020·Granted Oct 6, 2020·2 cites·20 claims
- 0985US10738128B2Antibodies that bind CD39 and uses thereofSURFACE ONCOLOGY INC·Filed 2019·Granted Aug 11, 2020·2 cites·19 claims
- 1083US10227413B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Mar 12, 2019·2 cites·20 claims
- 1182US10507244B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2017·Granted Dec 17, 2019·3 cites·24 claims
- 1281US11186644B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2019·Granted Nov 30, 2021·1 cites·11 claims
- 1381US2024043542A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1479US11655303B2Anti-CD39 antibody compositions and methodsSURFACE ONCOLOGY INC·Filed 2020·Granted May 23, 2023·1 cites·19 claims
- 1575US2023312712A1Anti-trem2 antibodies and methods of use thereofALECTOR LLC·Filed 2023·Application pending·0 cites
- 1672US2023013293A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1771US2022162309A1Anti-cd33 antibodies and methods of use thereofALECTOR LLC·Filed 2022·Application pending·0 cites
- 1868US2022098312A1Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1966US2020399394A1Antibodies That Bind CD39 and Uses ThereofSURFACE ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2065US2024425607A1Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancerCOMPUGEN LTD·Filed 2024·Application pending·0 cites
- 2163US2025297018A1Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancerCOMPUGEN LTD·Filed 2023·Application pending·0 cites
- 2263US2025381255A1Anti-asgr1 polypeptides and methods of use for immune toleranceANOKION SA·Filed 2023·Application pending·0 cites
- 2361US11590224B2Anti-TIGIT antigen-binding proteins and methods of uses thereofPOTENZA THERAPEUTICS INC·Filed 2019·Granted Feb 28, 2023·0 cites·8 claims
- 2461US2025382359A1Targeting gdf15-gfral pathwayBYOMASS INC·Filed 2022·Application pending·0 cites
- 2561US2025109190A1Myeloproliferative conditionsBYOMASS INC·Filed 2023·Application pending·0 cites
- 2661US2025019427A1Anti-gdf15 antibodies, compositions and uses thereofBYOMASS INC·Filed 2022·Application pending·0 cites
- 2758US2021269542A1Anti-gitr antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2858US2025270323A1Hhla2 binding agents with novel activityNEXTPOINT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2955US2023272082A1Anti-vista antibodies and uses thereofSENSEI BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3052US10988545B2Anti-GITR antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Apr 27, 2021·0 cites·11 claims
- 3142US2016340415A1ANTIBODIES DIRECTED AGAINST THE LukGH (LukAB) TOXIN OF STAPHYLOCOCCUS AUREUS AND ANTIBODY SEQUENCESARSANIS BIOSCIENCES GMBH·Filed 2014·Application pending·0 cites
- 3240US11453720B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Sep 27, 2022·0 cites·21 claims
- 3330US2018105584A1Antibody directed against immunoglobulin-binding proteins of s. aureusARSANIS BIOSCIENCES GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nels P. Nielson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →